SynthesisObesity surgery2026
Hormone PYY does not Explain the Variability in Weight Loss After Roux-en-Y Gastric Bypass: Evidence From a Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeptide YY (PYY) plays a key role in postprandial satiety and is markedly increased after Roux-en-Y gastric bypass (RYGB). While GLP-1 has been widely studied, the role of PYY as a predictor of weight loss success remains unclear. Some patients are considered non-responders, achieving < 50% excess BMI loss (EBMIL) or experiencing significant weight regain. This systematic review and meta-analysis aimed to compare fasting PYY levels and postprandial area under the curve (AUC) between RYGB responders and non-responders.
methodsFollowing PRISMA guidelines, PubMed, Embase, and Cochrane databases were searched for observational or interventional studies assessing PYY in adult RYGB patients stratified by weight loss response. Primary outcomes were fasting PYY levels and PYY AUC after standardized meals. Random-effects meta-analysis was conducted using Review Manager 5.4. Mean differences (MD) with 95% confidence intervals (CI) were calculated. Heterogeneity was assessed via Cochran’s Q and I².
resultsFive studies were included in the systematic review (92 non-responders and 89 responders), contributing to the fasting PYY meta-analysis, which showed no significant difference between groups (MD 1.71 pg/mL; 95% CI − 5.22 to 8.63; I² = 0%). Four studies reported AUC, also showing no difference (MD 53.16 pg·min/mL; 95% CI − 1726.29 to 1832.61; I² = 0%). Several studies observed lower satiety scores and attenuated appetite suppression in non-responders despite similar PYY profiles. No significant genetic variants in PYY or its receptor were associated with weight loss outcomes.
conclusionRYGB responders and non-responders have comparable fasting and postprandial PYY concentrations. These findings suggest that differential weight loss after RYGB is likely mediated by factors beyond PYY secretion, including neural, behavioral, or other hormonal mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.